Trasylol 10.000 KIE/ml injektions-/infusionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

trasylol 10.000 kie/ml injektions-/infusionsvæske, opløsning

nordic group b.v. - aprotinin - injektions-/infusionsvæske, opløsning - 10.000 kie/ml

Teysuno Den Europæiske Union - dansk - EMA (European Medicines Agency)

teysuno

nordic group b.v. - tegafur, gimeracil, oteracil - mave neoplasmer - antineoplastiske midler - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.